Pfizer Inc says it will maintain its supply of medicines to Russia but it will not initiate new clinical trials in the country, while Bayer is suspending investment projects and new-business development in that market.
Shanghai Pharma and Biocad established a joint venture to commercialize the latter’s portfolio of biosimilars and biologic treatments for the Chinese market.
CSL Behring will target growing Russian demand for protein-based therapies through a new Moscow office but says for now there are no plans for a local manufacturing site.
International GMP standard facilities and six biopharma centres will lead Russia’s initiative in implementing its Pharma 2020 policy, according to statements at this year’s BIO International Convention.
Detailed market knowledge and an experienced CMO are still critical to successfully developing a biopharmaceutical or biosimilar according to Cobra Biologics.
Investors are funding the creation of a RUB1.6bn ($52m), 10,000 sq m preclinical Russian CRO to fill the gap in the nation’s development chain and undercut western prices by 40 per cent.